fumeina vorolanib tablets 100mg per tablet

Description

Indication & Scope

Vorolanib is an oral multi-target anti-angiogenic tyrosine kinase inhibitor for adult patients with advanced RCC who failed prior TKI therapy, applied in second-line targeted treatment of renal cell carcinoma and must be used in combination with everolimus.

Mechanism
As a novel multi-target tyrosine kinase inhibitor, it selectively suppresses VEGFR, PDGFR, c-Kit and FLT3 to block tumor angiogenesis and inhibit proliferation of renal cancer cells.
Drug class
Class 1 innovative small-molecule chemical drug, multi-target anti-angiogenic TKI, renal cell carcinoma targeted therapeutic agent.
Clinical use
Phase III CONCEPT clinical trials verified its superior progression-free survival and controllable safety combined with everolimus; clinically administered orally at a daily dose of 200mg with food, the first domestic category 1 targeted drug exclusively approved for advanced renal cell carcinoma.

Specification

Generic Name	Vorolanib Tablets
Brand Name	FuMeiNa®
Ingredient	Vorolanib
Dosage Form	Film-coated Tablets
Package	100mg*20 tablets /box
Conditions Treated	Treatment combined with everolimus for adult patients with advanced RCC who have failed prior tyrosine kinase inhibitor therapy, to be used in combination with everolimus
Taboos	Contraindicated for patients with hypersensitivity to the active ingredient or any excipients of this product, or those with severe allergic history
Place of origin	Zhejiang, China
Priscription Type	Prescription drug (Rx)
Storage Conditions	Seal tightly, store below 30℃, avoid light
Manufacturer	Betta Pharmaceuticals Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	H20230013
Date of Revision	June 07, 2023
Shelf Life	36 months

How to use ?

Recommended Dose:200mg taken orally once daily with food, combined with everolimus 5mg once daily at the same meal; reduce to 100mg daily when co-administered with strong CYP3A4 inhibitors. Take the tablet whole without splitting or crushing.
Time: Take at a fixed daily mealtime; skip the missed dose if less than 12 hours remain before the next scheduled administration, do not double the dose next time. Continue treatment until disease progression or intolerable toxicity.
Interaction: Oral tablet administration only, intravenous injection forbidden. Avoid strong CYP3A4 inhibitors and strong CYP3A4 inducers throughout treatment. Must be used in combination with everolimus for the approved indication of advanced RCC.
Side effects:Mild, persistent reactions common: proteinuria, thrombocytopenia, diarrhea, fatigue, stomatitis, hypertension, hair discoloration. Rare interstitial lung disease, severe liver function injury; severe anaphylaxis very rare.

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support